Chenglong Han

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Juvenile Idiopathic Arthritis

Top Venues

Rheumatology and therapy

The Journal of dermatological treatment

American journal of clinical dermatology

Journal of patient-reported outcomes

This page only lists publications with an associated author ORCID identifier.

Publications

Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy (2024)
Brian G Feagan, William J Sandborn, Bruce E Sands, Yan Liu, Marion Vetter, Susan D Mathias, Kuan-Hsiang Gary Huang, Jewel Johanns, Matthew Germinaro, Chenglong Han
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease. Journal of patient-reported outcomes 7 (1) (2023)
Kristian Reich, April W Armstrong, Peter Foley, Michael Song, Megan Miller, Y K Shen, Yin You, Chenglong Han, Kenneth B Gordon
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. American journal of clinical dermatology 21 (6) (2021)
Proton Rahman, Philip J Mease, Philip S Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P Kollmeier, Elizabeth C Hsia, Bei Zhou, Xiwu Lin, May Shawi, Chetan S Karyekar, Chenglong Han
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis research & therapy 23 (1) (2021)
Christopher Ernest Maitland Griffiths, Kim A Papp, Michael Song, Megan Miller, Yin You, Yaung-Kaung Shen, Chenglong Han, Andrew Blauvelt
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. The Journal of dermatological treatment (2020)
Laura K Ferris, Elyssa Ott, Jingzhi Jiang, H Chih-Ho Hong, Shu Li, Chenglong Han, Wojciech Baran
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. The Journal of dermatological treatment 31 (2) (2019)
Kristian Reich, Peter Foley, Chenglong Han, Sean McElligott, Erik Muser, Nan Li, April W Armstrong
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. The Journal of dermatological treatment 31 (6) (2019)